Cancer hopeful neratinib plagued by diarrhea, analysis shows, but Puma cites a solution | Fierce Pharma
Why Puma Biotechnology, Inc. Stock Crashed 37% in March | Fox Business
Here's Why The Puma Biotechnology Inc (NYSE:PBYI) Pullback Might Be A Buy-In Opportunity - Market Exclusive
Puma Biotechnology: Who Are They? What Happened? And, Where Are They Going? (NASDAQ:PBYI) | Seeking Alpha
Neratinib Plus Capecitabine Approved for HER2-Positive Metastatic Breast Cancer
Puma Biotechnology | $PBYI Stock | Shares Climb Up as Company Announced FDA Approval for NERLYNX - Warrior Trading News
Marketing Application for Early Stage Breast Cancer Therapy Neratinib Submitted to EMA by Puma Biotechnology - Breast Cancer News
Puma Biotechnology's Neratinib Set To Target Extended Adjuvant Opportunity (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer at the ESMO Congress 2022 | Business Wire
Puma Biotech's Neratinib Fails To Extend Overall Survival In Brain Cancer Trial
Puma Biotechnology Surging
Puma Biotechnology
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology, Inc. - Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer
Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet
Puma Biotechnology, Inc. - Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2019 SABCS
Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual Meeting
Puma Biotechnology
Neratinib in Early-Stage Breast Cancer: A Profile of Its Use in the EU | SpringerLink
Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer at the ESMO Congress 2022 | Business Wire
Puma Biotechnology, Inc.
HER2+ Breast Cancer Patients' Access to Neratinib Expanded Through Puma's EAP
Puma Biotechnology - Crunchbase Company Profile & Funding
Puma Biotechnology Presents Interim Results from the Biliary Tract Cancers Cohort of the Phase II SUMMIT “Basket” Trial of Neratinib at ASCO GI | Business Wire
Neratinib Chapter
JP Morgan Healthcare, Day 3: Puma Biotechnology, Natera | Precision Oncology News
Puma Biotechnology Presents Updated Results from the Phase II SUMMIT Trial of Neratinib for HER2-Mutant, HR-Positive Metastatic Breast Cancer at SABCS 2020 | Business Wire
Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2019 SABCS | Business Wire
